B+
Bull case
20%
Probability
Target price
$12.00
+104.8% vs current
AARD
Aardvark TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$5.75
-1.9% vs current
B-
Bear case
35%
Probability
Target price
$3.50
-40.3% vs current
AI sentiment snapshot
Latest data as of 2026-07-17
Recent news sentiment (30D)
-0.8
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+51.9
Score
AI commentary
News tone is negative because the lead programs remain paused and the cardiac-safety review is unresolved. Social, options, short-interest, employee-review, and post-print price-reaction data are unavailable in the packet; missing analyst reaction is not treated as positive evidence. The peer set is generic, so this remains a low-coverage, monitoring-style setup.
RankAlpha Sentiment Codex - 2026-07-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-15eventFDA and company update on program pathHigh impact
Aardvark said it was working with the FDA and expected further guidance on ARD-101 and ARD-201 in Q2 2026; the packet does not confirm a subsequent update, leaving timing and restart criteria uncertain. [#SEC-8K-2026-05-07]
2026-10-15catalystClinical pauses and unresolved cardiac-safety reviewHigh impact
ARD-101 Phase 3 HERO/OLE enrollment and dosing, and ARD-201 development, remain voluntarily paused after unexpected reversible cardiac observations in a healthy-volunteer study. The unresolved safety path creates near-term downside asymmetry. [#SEC-8K-2026-05-07]
2027-07-17catalystRunway supports safety-resolution effortsHigh impact
Cash, cash equivalents and short-term investments were $91.2 million at March 31, 2026, which management said could fund operations into mid-2027. This provides time to pursue regulatory and clinical clarification, but does not reduce the core clinical binary risk. [#SEC-8K-2026-05-07]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology